Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Crism TherapeuticsLSE:CRTX -5.00% Market Cap is £7.52 Mil as of Jul. 20, 2026. The stock has 3 warning signs investors should review. Among 1,423 Biotechnology companies, Crism Therapeutics ranks worse than 84.05% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Crism Therapeutics's share price for the quarter that ended in Dec. 2025 was £0.1. Crism Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 51.74 Mil. Therefore, Crism Therapeutics's market cap for the quarter that ended in Dec. 2025 was £5.17 Mil.
Crism Therapeutics's quarterly market cap
increased
from Dec. 2024 (£3.59 Mil) to Jun. 2025 (£4.52 Mil) and
increased
from Jun. 2025 (£4.52 Mil) to Dec. 2025 (£5.17 Mil).
Crism Therapeutics's annual market cap
increased
from Dec. 2023 (£1.25 Mil) to Dec. 2024 (£3.59 Mil) and
increased
from Dec. 2024 (£3.59 Mil) to Dec. 2025 (£5.17 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Crism Therapeutics's Enterprise Value for Today is £6.24 Mil.
Crism Therapeutics (LSE:CRTX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Crism Therapeutics Market Cap Related Terms
Crism Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Crism Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:CRTX vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Crism Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crism Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Crism Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Crism Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Crism Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crism Therapeutics (LSE:CRTX) has a Market Cap of £7.52 Mil as of Jul. 20, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Crism Therapeutics and its competitors. According to the industry distribution chart, Crism Therapeutics ranks #1196 out of 1423 companies in the Biotechnology industry, placing it in the top 84%.
Is Crism Therapeutics' Market Cap too high?
Crism Therapeutics' current Market Cap is £7.52 Mil. Based on the distribution chart, Crism Therapeutics ranks #1196 out of 1423 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Crism Therapeutics' Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Crism Therapeutics ranks #1196 out of 1423 companies for Market Cap. This places Crism Therapeutics in the lower half of its industry. The industry median Market Cap is 113.11. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.11, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Crism Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 113.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Crism Therapeutics's current Market Cap is £7.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crism Therapeutics stock overvalued right now?
Crism Therapeutics (LSE:CRTX) has a current Market Cap of £7.52 Mil. The current Market Cap is £7.52 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Crism Therapeutics (LSE:CRTX), the current Market Cap is £7.52 Mil as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Crism Therapeutics Corp has developed a drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. Its product ChemoSeed which is in its clinical trial phase, can be implanted directly into the tumour or the resection margin following the removal of a tumour. The company also provides consultancy and formulation services to its clients assisting them with pharmaceutical formulation and development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:CRTX has been successfully added to your 
